共 155 条
[1]
Nair R(2018)The promise of CAR T-cell therapy in aggressive B-cell lymphoma Best Pract Res Clin Haematol 31 293-298
[2]
Neelapu SS(2018)Axicabtagene ciloleucel, a first-in-class CAR T-cell therapy for aggressive NHL Leuk Lymphoma 59 1785-1796
[3]
Roberts ZJ(2010)Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 Blood 116 4099-4102
[4]
Better M(2011)Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia N Engl J Med 365 725-733
[5]
Bot A(2013)Chimeric antigen receptor-modified T cells for acute lymphoid leukemia N Engl J Med 368 1509-1518
[6]
Roberts MR(2019)Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma N Engl J Med 380 45-56
[7]
Ribas A(2018)Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia N Engl J Med 378 439-448
[8]
Kochenderfer JN(2016)Efficacy and safety of CTL019 in the first US phase II multicenter trial in pediatric relapsed/refractory acute lymphoblastic leukemia: results of an interim analysis Blood 126 681-S264
[9]
Wilson WH(2017)Global registration trial of efficacy and safety of CTL019 in pediatric and young adult patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL): update to the interim analysis Clin Lymphoma Myeloma Leuk 17 S263-1506
[10]
Janik JE(2017)New development in CAR T-cell therapy J Hematol Oncol 10 53-416